Spontaneous remission in thyroid cancer patients after biochemical incomplete response to initial therapy
Top Cited Papers
- 6 June 2012
- journal article
- research article
- Published by Wiley in Clinical Endocrinology
- Vol. 77 (1), 132-138
- https://doi.org/10.1111/j.1365-2265.2012.04342.x
Abstract
To validate the American Thyroid Association (ATA) initial risk of recurrence scheme and the Memorial Sloan Kettering Cancer Center (MSKCC) response to therapy re‐stratification approach in a large cohort of patients with differentiated thyroid cancer (DTC) treated outside of the United States. Retrospective chart review. Five hundred and six patients with DTC followed for a median of 10 years after total thyroidectomy and RAI remnant ablation at a major cancer centre in Brazil. Final clinical outcomes were assessed based on American Joint Cancer Committee (AJCC)/Union Internationale Contre le Cancer (UICC) staging, ATA risk stratification and response to therapy assessment (excellent, acceptable, biochemical incomplete and structural incomplete). The AJCC/UICC staging system did not adequately stratify patients with regard to the risk of recurrence/persistent disease. However, the ATA system demonstrated a 13% risk of recurrent/persistent disease in low‐risk patients, 36% in intermediate risk patients, and 68% in high‐risk patients. Furthermore, an excellent response to therapy decreased the risk of recurrent/persistent disease to 1·4%. At the time of final follow‐up, 34% of the biochemical incomplete response patients had been re‐classified as having no evidence of disease (NED) without having received any additional therapy beyond continue levothyroxine suppression. Conversely, even after additional therapies, only 9% of the patients with an incomplete structural response were eventually re‐classified as NED. These data validate the ATA risk classification as an excellent initial predictor of recurrent/persistent disease and confirm the clinical utility of the MSKCC dynamic risk assessment system in a cohort of patients evaluated and treated outside the United States.Keywords
This publication has 21 references indexed in Scilit:
- Estimating Risk of Recurrence in Differentiated Thyroid Cancer After Total Thyroidectomy and Radioactive Iodine Remnant Ablation: Using Response to Therapy Variables to Modify the Initial Risk Estimates Predicted by the New American Thyroid Association Staging SystemThyroid®, 2010
- Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid CancerThyroid®, 2009
- Influence of age and primary tumor size on the risk for residual/recurrent well‐differentiated thyroid carcinomaHead & Neck, 2009
- Nódulos de tireóide e câncer diferenciado de tireóide: consenso brasileiroArchives of Endocrinology and Metabolism, 2007
- European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epitheliumActa Endocrinologica, 2006
- A model for predicting outcomes in patients with differentiated thyroid cancer and model performance in comparison with other classification systemsJournal of the American College of Surgeons, 2005
- A novel classification system for patients with PTC: addition of the new variables of large (3 cm or greater) nodal metastases and reclassification during the follow-up periodSurgery, 2004
- Presidential address: Beyond risk groups—A new look at differentiated thyroid cancerSurgery, 1998
- Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scanJournal of Clinical Endocrinology & Metabolism, 1995
- A prognostic index for thyroid carcinoma. A study of the E.O.R.T.C. thyroid cancer cooperative groupEuropean Journal of Cancer (1965), 1979